Curcuminoids purified from turmeric powder modulate the function of human multidrug resistance protein 1 (ABCC1)

Wanida Chearwae1, Chung-Pu Wu, H-Y Chu

  • 1Department of Biochemistry, Faculty of Medicine, Chiang Mai University, Thailand.

Insights

Curcuminoids from turmeric inhibit multidrug resistance protein 1 (MRP1), a key factor in chemotherapy failure. Curcumin I is the most effective MRP1 inhibitor, potentially improving cancer treatment efficacy.

Area of Science:

  • Biochemistry
  • Pharmacology
  • Molecular Biology

Background:

  • Multidrug resistance (MDR) is a significant challenge in cancer chemotherapy.
  • Overexpression of drug efflux pumps, like multidrug resistance protein 1 (MRP1/ABCC1), is a primary MDR mechanism.
  • Identifying modulators of MRP1 function is crucial for overcoming chemotherapy resistance.

Purpose of the Study:

  • To investigate the ability of curcuminoids to modulate the function of MRP1.
  • To determine the efficacy of curcumin I, II, and III, and a curcumin mixture in inhibiting MRP1-mediated drug efflux.
  • To elucidate the interaction mechanism of curcuminoids with MRP1.

Main Methods:

  • Utilized HEK293 cells stably transfected with MRP1 or a control vector.
  • Assessed the effect of curcuminoids on etoposide sensitivity in MRP1-expressing cells.
  • Analyzed MRP1 protein levels using Western blot.
  • Measured the efflux of fluorescent substrates (calcein-AM, fluo4-AM) and ATP hydrolysis activity of MRP1.

Main Results:

  • Curcuminoids increased etoposide sensitivity in MRP1-expressing cells severalfold without altering MRP1 protein levels.
  • Curcuminoids inhibited the efflux of fluorescent substrates in a concentration-dependent manner, with curcumin I being the most potent.
  • Curcuminoids stimulated basal MRP1 ATPase activity and inhibited quercetin-stimulated ATP hydrolysis, suggesting interaction at the substrate-binding site.

Conclusions:

  • Curcuminoids effectively inhibit MRP1-mediated transport, offering a potential strategy to overcome MDR in cancer.
  • Curcumin I, a major component of turmeric, demonstrates the strongest inhibitory effect on MRP1 function.
  • These findings highlight the therapeutic potential of curcuminoids in enhancing chemotherapy efficacy.

Related Concept Videos

Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters01:16

Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters

The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...
Carrier-Mediated Transport01:06

Carrier-Mediated Transport

Carrier-mediated transport is a pivotal process in drug absorption, particularly for lipid-insoluble drugs, and encompasses facilitated diffusion and active transport. Facilitated diffusion allows drugs to move along their concentration gradient without energy expenditure, while active transport utilizes ATP to drive drug movement against this gradient.
Active transport involves two types of membrane-spanning transporters: uptake and efflux. Uptake transporters are expressed in the small...
ABC Transporters: Exporter01:31

ABC Transporters: Exporter

ATP-binding cassette or ABC transporter is the largest superfamily of integral membrane proteins. The transporters have transmembrane-binding domains (TMDs) and nucleotide-binding domains (NBDs). The TMDs are specific to their substrates, whereas the NBDs are similar to engines that complete ATP hydrolysis to complete the substrate transport. They can be full transporters consisting of two TMDs and NBDs, half transporters with one TMD and NBD, while some encoded with a single TMD or NBD are...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase01:27

Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase

Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...